Groowe Groowe BETA / Newsroom
⏱ News is delayed by 15 minutes. Sign in for real-time access. Sign in

Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035 - United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate

globenewswire.com
UTHR Mentioned as a major market player in the pediatric neuroblastoma treatment market, indicating its involvement and potential stake in the sector's growth. PFE Listed as a major market player in the pediatric neuroblastoma treatment market, suggesting its participation and potential benefit from market expansion. AMGN Identified as a major market player in the pediatric neuroblastoma treatment sector, implying its role and potential growth within this market. JNJ Listed as a major market player in the pediatric neuroblastoma treatment market, suggesting its involvement and potential growth in this therapeutic area. ABBV Mentioned as a major market player in the pediatric neuroblastoma treatment market, indicating its participation and potential to capitalize on market growth. MRK Included as a major market player in the pediatric neuroblastoma treatment market, suggesting its role and potential to benefit from advancements in the sector. BMY Listed as a major market player in the pediatric neuroblastoma treatment market, indicating its presence and potential to contribute to or benefit from market trends. MAC Identified as a major market player in the pediatric neuroblastoma treatment market, suggesting its involvement and potential growth within this specific therapeutic area.

Pediatric Neuroblastoma Treatment Market Outlook 2026-2030 & 2035 - United Therapeutics Corporation, APEIRON Biologics, Pfizer, Bayer, and Amgen Dominate Dublin, April 02, 2026 (GLOBE NEWSWIRE) -- The "Pediatric Neuroblastoma Treatment Market Report 2026" has been added to ResearchAndMarkets.com's offering. The report provides a detailed analysis of market size, regional shares, competitor strategies, and trends.

The pediatric neuroblastoma treatment market has demonstrated substantial growth, increasing from $2.02 billion in 2025 to a projected $2.2 billion in 2026, at a CAGR of 9%. Historical growth factors include limited access to oncology drugs, low adoption of immunotherapy, reliance on conventional chemotherapy, limited specialized centers, and fragmented clinical data.

Looking forward, the market is expected to reach $3.13 billion by 2030, growing at a 9.2% CAGR. This growth is driven by enhanced R&D in targeted therapies, increased use of CAR T-cell and monoclonal antibodies, rising adoption of personalized medicine, and expanded investment in oncology infrastructure. Other growth catalysts include awareness programs for early detection, AI in diagnostics, genomics-based therapies, cloud and big data integration for patient management, IoT-enabled monitoring, and innovations in drug production.

The growing number of new neuroblastoma cases will significantly drive market expansion. The rising prevalence is fueling demand for effective treatments, motivating pharmaceutical companies to invest in R&D and foster innovation. Advanced diagnostics and screening technologies now allow for earlier neuroblastoma detection, supporting timely interventions and improved clinical outcomes. Data from the American Society of Clinical Oncology highlights that neuroblastoma affects 700 to 800 children annually in the US alone, accounting for 6% of all childhood cancers.

Leading companies are advancing technologies like antibody-based approaches, enhancing therapy effectiveness and patient outcomes. Renaissance Pharma Ltd introduced Hu14.18K322A, targeting GD2 on neuroblastoma cells, enhancing immune attack on tumors. Moreover, Serb Pharmaceuticals' acquisition of Y-mAbs Therapeutics aims to bolster its pediatric oncology portfolio, particularly through DANYELZA, a flagship anti-GD2 monoclonal antibody for high-risk cases.

Major market players include United Therapeutics Corporation, APEIRON Biologics AG, Pfizer Inc., MacroGenics Inc., Bayer AG, Y-mAbs Therapeutics Inc., Amgen Inc., Eli Lilly, F. Hoffmann-La Roche AG, Novartis AG, Johnson & Johnson, AbbVie Inc., Merck & Co., Bristol-Myers Squibb, Takeda Pharmaceutical, Daiichi Sankyo, and Eisai Co.

In 2025, North America led the market. Regions covered include Asia-Pacific, Europe, North and South America, the Middle East, and Africa. Countries in focus include the US, UK, Germany, France, China, India, and Japan.

Reasons to Purchase:

Report Scope:

Companies: United Therapeutics Corporation, APEIRON Biologics AG, Pfizer Inc., Bayer AG, Amgen Inc., Novartis AG, and more.

Countries: Australia, Brazil, China, France, India, Japan, Taiwan, UK, USA, among others.

Regions: Asia-Pacific, Western Europe, North America, Middle East, Africa

Time Series: Five years historic and ten years forecast.

Key Attributes

The companies featured in this Pediatric Neuroblastoma Treatment market report include:

For more information about this report visit https://www.researchandmarkets.com/r/wahoih

About ResearchAndMarkets.com

ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment